Stay updated with breaking news from Thyroid Eye Disease Program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Patients with thyroid eye disease who used the minimally invasive insulin-like growth factor I blocking antibody, teprotumumab, experienced improvement in their
- Clinical and in vitro data presented in three late-breaking presentations at ATA provide emerging evidence of VRDN-001 efficacy and differentiation
An anti-IGF-1R antibody VRDN-001developed by Viridian Therapeutics has succeeded in a phase I/II clinical trial of people with active thyroid eye disease, with participants seeing an average 2.4 mm...
Patients with active thyroid eye disease (TED) could benefit from rapid, significant improvements after positive data emerged from a trial.
Are your eyes dry, uncomfortable, and bulging? You could have thyroid eye disease, especially if you already have Graves’ disease. Learn more about TED.